Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 5/20 | 0.48 |
| ▸ | POLB | P06746 | 4/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | XDH | P47989 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.46 |
| ▸ | RELA | Q04206 | 1/20 | 0.46 |
| ▸ | FUT7 | Q11130 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10945485 | 0.86 | CA1 (0.56) | KDM4EMAPTGAAPOLBALDH1A1 | |
| SCHEMBL9595637 | 0.81 | POLB (0.59) | KDM4EMAPTGAAPOLBRECQL | |
| SCHEMBL29546667 | 0.81 | POLB (0.68) | KDM4EMAPTGAAPOLBRECQL | |
| SCHEMBL18105229 | 0.81 | POLB (0.68) | KDM4EMAPTGAAPOLBRECQL | |
| SCHEMBL11519523 | 0.81 | CYP3A4 (0.50) | KDM4EMAPTGAAPOLBALDH1A1 | |
| SCHEMBL24379065 | 0.81 | GAA (0.54) | KDM4EGAAPOLBRECQLALDH1A1 | |
| SCHEMBL9145572 | 0.81 | KDM4E (0.55) | KDM4EMAPTGAAPOLBALDH1A1 | |
| SCHEMBL21821414 | 0.80 | MAPT (0.47) | KDM4EMAPTGAAPOLBALDH1A1 | |
| SCHEMBL20076080 | 0.80 | KDM4E (0.47) | KDM4EMAPTGAAPOLBRECQL | |
| SCHEMBL31198748 | 0.80 | KDM4E (0.47) | KDM4EMAPTGAAPOLBRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE45548-E1 | Functionalized drugs and polymers derived therefrom | BEZWADA BIOMEDICAL, LLC (US) | 2015-06-09 | — | — | US | disclosed |
| US-8802892-B2 | Functionalized phenolic compounds and polymers therefrom | BEZWADA BIOMEDICAL, LLC (US) | 2014-08-12 | — | — | US | disclosed |
| US-20130281652-A1 | FUNCTIONALIZED PHENOLIC COMPOUNDS AND POLYMERS THEREFROM | BEZWADA BIOMEDICAL, LLC | 2013-10-24 | — | — | US | disclosed |
| US-8409559-B2 | Functionalized drugs and polymers derived therefrom | Bezwada Biomedical, Inc. (US) | 2013-04-02 | — | — | US | disclosed |
| US-8318973-B2 | Functionalized sinapic acid and methyl sinapate | BEZWADA BIOMEDICAL, LLC (US) | 2012-11-27 | — | — | US | disclosed |
| US-20100152272-A1 | FUNCTIONALIZED DRUGS AND POLYMERS THEREFROM | BEZWADA BIOMEDICAL, LLC (US) | 2010-06-17 | — | — | US | disclosed |
| US-7691364-B2 | Functionalized drugs and polymers derived therefrom | BEZWADA BIOMEDICAL, LLC (US) | 2010-04-06 | — | — | US | disclosed |
| US-20090170927-A1 | FUNCTIONALIZED PHENOLIC COMPOUNDS AND POLYMERS THEREFROM | BEZWADA BIOMEDICAL, LLC (US) | 2009-07-02 | — | — | US | disclosed |
| EP-1931334-A2 | FUNCTIONALIZED DRUGS AND POLYMERS DERIVED THEREFROM | Bezwada Biomedical LLC (US) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007030538-A2 | FUNCTIONALIZED DRUGS AND POLYMERS DERIVED THEREFROM | BEZWADA BIOMEDICAL LLC (US) | 2007-03-15 | — | — | WO | disclosed |
| US-20060172983-A1 | Functionalized drugs and polymers derived therefrom | BEZWADA BIOMEDICAL, LLC (US) | 2006-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152272-A1 | FUNCTIONALIZED DRUGS AND POLYMERS THEREFROM | OGFR, LOX, DDO | KDM4E 1379/4885MAPT 923/4885GAA 876/4885 |
| US-20090170927-A1 | FUNCTIONALIZED PHENOLIC COMPOUNDS AND POLYMERS THEREFROM | COMT, AOX1, UGT1A6 | KDM4E 1444/4885MAPT 2351/4885GAA 450/4885 |
| US-20060172983-A1 | Functionalized drugs and polymers derived therefrom | OGFR, LOX, OPRM1 | KDM4E 1584/4885MAPT 579/4885GAA 804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.